(2011) Prediction of hepatitis B virus lamivudine resistance based on YMDD sequence data using an artificial neural network model. Hepatitis Monthly. pp. 108-113. ISSN 1735-143X
Full text not available from this repository.
Abstract
Background: Hepatitis B virus (HBV) infection is an important health problem worldwide with critical outcomes. The nucleoside analog lamivudine (LMV) is a potent inhibitor of HBV polymerase and impedes HBV replication in patients with chronic hepatitis B. Treatment with LMV for long periods causes the appearance and reproduction of drug-resistant strains, rising to more than 40 after 2 years and to over 50 and 70 after 3 and 4 years, respectively. Objectives: Artificial neural networks (ANNs) were used to make predictions with regard to resistance phenotypes using biochemical and biophysical features of the YMDD sequence. Patients and Methods: The study population comprised patients who were intended for surgery in various hospitals in Tehran-Iran. An ACRS-PCR method was performed to distinguish mutations in the YMDD motif of HBV polymerase. In the training and testing stages, these parameters were used to identify the most promising optimal network. The ideal values of RMSE and MAE are zero, and a value near zero indicates better performance. The selection was performed using statistical accuracy measures, such as root mean square error (RMSE), coefficient of determination (R2), and mean absolute error (MAE). The main purpose of this paper was to develop a new method based on ANNs to simulate HBV drug resistance using the physiochemical properties of the YMDD motif and compare its results with multiple regression models. Results: The results of the MLP in the training stage were 0.8834, 0.07, and 0.09 and 0.8465, 0.160.04 in the testing stage; for the total data, the values were 0.8549, 0.115, and 0.065, respectively. The MLP model predicts lamivudine resistance in HBV better than the MLR model. Conclusions: The ANN model can be used as an alternative method of predicting the outcome of HBV therapy. In a case study, the proposed model showed vigorous clusterization of predicted and observed drug responses. The current study was designed to develop an algorithm for predicting drug resistance using chemiophysical data with artificially created neural networks. To this end, an intelligent and multidisciplinary program should be developed on the basis of the information to be gained on the essentials of different applications by similar investigations. This program will help design expert neural network architectures for each application automatically. (c) 2011 Kowsar M.P.Co. All rights reserved.
Item Type: | Article | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Creators: |
|
||||||||||||||||||
Keywords: | Drug resistance Lamivudine Neural network models hiv-1 drug-resistance reverse-transcriptase motif variants genotype mutants emergence adefovir therapy assay Gastroenterology & Hepatology | ||||||||||||||||||
Divisions: | |||||||||||||||||||
Page Range: | pp. 108-113 | ||||||||||||||||||
Journal or Publication Title: | Hepatitis Monthly | ||||||||||||||||||
Journal Index: | ISI | ||||||||||||||||||
Volume: | 11 | ||||||||||||||||||
Number: | 2 | ||||||||||||||||||
ISSN: | 1735-143X | ||||||||||||||||||
Depositing User: | مهندس مهدی شریفی | ||||||||||||||||||
URI: | http://eprints.medilam.ac.ir/id/eprint/854 |
Actions (login required)
View Item |